Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2039

Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.

Patents
1,782

Quick answer

1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10450364

    Hyperimmunized egg product for treatment of necrotic enteritis in poultry

    United States of America as represented by the Secretary of the Air Force · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10450572

    Androgen receptor variant inhibitors and methods of using

    Regents of the University of Minnesota · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10450372

    Anti-thyroglobulin T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10450565

    Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. CA 3097087

    COMBINAISON COMPRENANT UN INHIBITEUR DE HDAC, UN INHIBITEUR DE LAG-3 ET UN INHIBITEUR DE PD-1 OU UN INHIBITEUR DE PD-L1 POUR LE TRAITEMENT DU CANCER

    4SC AG [DE] · Granted Thu Oct 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10457745

    Anti-complement C1s antibodies

    Bioverativ USA Inc. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10456461

    Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10457726

    Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof

    UNIVERSITY OF CONNECTICUT · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10457725

    Methods of treating skin cancer by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10457945

    UNA oligomers for therapeutics with prolonged stability

    ARCTURUS THERAPEUTICS, INC. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10457701

    Sialic acid analogs

    Ultragenyx Pharmaceutical Inc. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10456392

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10456448

    PTD-SMAD7 therapeutics

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10456340

    Liquid-impregnated nonwoven fabric which contains zinc oxide-containing cellulose fibers

    LENZING AKTIENGESELLSCHAFT · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10455849

    Method for the preparation of a protein peptide, a protein peptide and use thereof

    INFINITUS (CHINA) COMPANY LTD. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10456292

    Compositions and methods relating to an occlusive polymer hydrogel

    Revolution Contraceptives LLC · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10456333

    Dental adhesive

    KURARAY NORITAKE DENTAL INC. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10456412

    Lipid extraction processes

    AKER BIOMARINE ANTARCTIC AS · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10456408

    Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

    ESSENTIALIS, INC. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10456471

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10456373

    Agent exhibiting anti-stress, anxiolytic and anti-depression activity, and composition based thereon

    OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU “NORMOFARM” · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10456390

    Combinations comprising MABA compounds and corticosteroids

    Almirall, S.A. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10457676

    Capsazepine analogs for the treatment of cancer and other proliferative diseases

    The Board of Regents of the University of Texas System · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10457662

    Substituted amides for treating and preventing cancer

    The Board of Regents of the University of Texas System · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10456476

    Method involving 1-benzotriazolyl carbonate esters of poly(ethylene glycol)

    Nektar Therapeutics · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10457654

    Therapeutic compounds and methods of use thereof

    Xenon Pharmaceuticals Inc. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10456473

    Lipid compositions

    ARBUTUS BIOPHARMA CORPORATION · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10456380

    Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists

    Cumberland Pharmaceuticals Inc. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10456406

    Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb

    VTV THERAPEUTICS LLC · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10456404

    Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10456439

    NK3 agonist for use in the treatment of a patient suffering from atrial arrhythmia or fibrillation

    ACADEMISCH MEDISCH CENTRUM · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10457670

    Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10457703

    Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10456346

    Cosmetic formulations for topical applications containing erythropoietin-derived molecules

    ASC REGENITY LIMITED · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. CA 3097885

    PROCEDES ET COMPOSITIONS D'EPUISEMENT DE LYMPHOCYTES T CYTOTOXIQUES

    CRISPR THERAPEUTICS AG [CH] · Granted Thu Oct 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. CA 3098014

    CELLULES CAR-T ANTI-BCMA POUR DEPLETION DE CELLULES PLASMATIQUES

    CRISPR THERAPEUTICS AG [CH] · Granted Thu Oct 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10463684

    Nucleobase analogue derivatives and their applications

    The Board of Regents of the University of Texas System · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10464983

    Variants of adrenomedullin and calcitonin gene-related peptide and methods of use

    The Board of Regents of the University of Oklahoma · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10464992

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10464967

    Non-hormonal steroid modulators of NF-κβ for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10463749

    Maytansinoid derivatives, conjugates thereof, and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10464739

    Reduction in stress cracking of films

    Aquestive Therapeutics, Inc. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10463745

    Materials for tissue regeneration

    Northwestern University · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10464941

    Therapeutic compounds

    Regents of the University of Minnesota · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10464918

    Process of making somatostatin modulators

    CRINETICS PHARMACEUTICALS, INC. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10463744

    Polymer-semaxanib moiety conjugates

    Nektar Therapeutics · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10463734

    Nanoparticle therapy in cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10463718

    Adeno-associated virus factor VIII vectors

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2039?

1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.